Department of Neurology, the First Affiliated Hospital, Dalian Medical University, Dalian, China.
First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany.
J Alzheimers Dis. 2021;79(3):1317-1325. doi: 10.3233/JAD-201335.
Florbetapir (AV45) and fluorodeoxyglucose (FDG) PET imaging are valuable techniques to detect the amyloid-β (Aβ) load and brain glucose metabolism in patients with Alzheimer's disease (AD).
The purpose of this study is to access the characteristics of Aβ load and FDG metabolism in brain for further investigating their relationships with cognitive impairment in AD patients.
Twenty-seven patients with AD (average 70.6 years old, N = 13 male, N = 14 female) were enrolled in this study. These AD patients underwent the standard clinical assessment and received detailed imaging examinations of the nervous system by using Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), 18F-AV45, and 18F-FDG PET scans.
Of 27 AD patients, 22 patients (81.5%) showed significantly increases in Aβ load and 26 patients (96.3%) had significantly reductions in FDG metabolism. The moderate AD patients had more brain areas of reduced FDG metabolism and more severe reductions in some regions compared to mild AD patients, with no differences in Aβ load observed. Moreover, the range and degree of reduced FDG metabolism in several regions were positively correlated with the total score of MMSE or MOCA, whereas the range of Aβ load did not. No correlation was found between the range of Aβ load and the range of reduced FDG metabolism in this study.
The reduction in FDG metabolisms captured by 18F-FDG imaging can be used as a potential biomarker for AD diagnosis in the future. 18F-AV45 imaging did not present valuable evidence for evaluating AD patient in this study.
氟代脱氧葡萄糖（FDG）和氟代苯丙氨酸（AV45）正电子发射断层扫描（PET）成像技术可用于检测阿尔茨海默病（AD）患者的淀粉样蛋白（Aβ）负荷和脑葡萄糖代谢。
本研究旨在评估 AD 患者脑内 Aβ负荷和 FDG 代谢特征，进一步探讨两者与认知障碍的关系。
共纳入 27 例 AD 患者（平均年龄 70.6 岁，男 13 例，女 14 例）。所有患者接受了简易精神状态检查（MMSE）、蒙特利尔认知评估（MOCA）、18F-AV45 和 18F-FDG PET 等标准临床评估和详细的神经系统影像学检查。
27 例 AD 患者中，22 例（81.5%）Aβ负荷显著增加，26 例（96.3%）FDG 代谢显著降低。与轻度 AD 患者相比，中重度 AD 患者脑内 FDG 代谢降低的区域更多，某些区域的降低更明显，但 Aβ负荷无差异。此外，多个脑区 FDG 代谢降低的范围和程度与 MMSE 或 MOCA 的总分呈正相关，而 Aβ负荷的范围与认知评分无相关性。本研究中，Aβ负荷的范围与 FDG 代谢降低的范围之间无相关性。
18F-FDG 成像显示的 FDG 代谢降低可作为 AD 未来诊断的潜在生物标志物。18F-AV45 成像在本研究中对 AD 患者的评估没有提供有价值的证据。
